Drug Profile
Danazol transdermal
Alternative Names: FP-1198Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator FemmePharma
- Class Antiallergics; Eye disorder therapies; Oxazoles; Small molecules
- Mechanism of Action Estrogen receptor antagonists; Testosterone congener stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast pain
Most Recent Events
- 27 Jul 2015 Clinical development is ongoing in the USA
- 30 Jun 2011 FemmePharma completes a phase II trial in Breast pain in USA (NCT01105793)
- 23 Jun 2010 Phase-II clinical trials in Breast pain in USA (Transdermal)